R-Ras: A Potential Drug Target for Cancer (G6237)

Target Name: RRAS

NCBI ID: G6237

RRAS

R-Ras: A Potential Drug Target for Cancer

Ras-related protein (R-Ras) is a protein that is highly expressed in many types of cancer, including breast, ovarian, and prostate cancer. It is a key regulator of cell signaling pathways, including the TGF-β pathway, which is involved in cell growth, differentiation, and survival. The TGF-β pathway is a well-established target for many anti-cancer drugs, including inhibitors of the tyrosine kinase receptor (TKR) such as gefitinib and sorafenib.

R-Ras is a protein that is highly similar to the TGF-β receptor (TGR), which is a key regulator of cell signaling pathways. The TGR is a transmembrane protein that is composed of two subunits: an extracellular domain and an intracellular domain. The intracellular domain of TGR contains a tyrosine kinase domain, which is responsible for the binding of tyrosine hormones and other signaling molecules.

R-Ras is a protein that is highly similar to TGR, but it is missing an important structural domain known as the N-terminus. The N-terminus is the region of the protein that interacts with other proteins and is involved in the formation of complexes. The absence of the N-terminus of R-Ras has consequences for its function, as it is unable to form complexes with other proteins.

Despite its missing N-terminus, R-Ras is still able to interact with other proteins and participate in signaling pathways. It is a potent inhibitor of the TGF-β pathway and has been shown to inhibit the growth and survival of many types of cancer cells. R-Ras has also been shown to be involved in the regulation of cell adhesion and migration, as well as the regulation of the Wnt signaling pathway.

In addition to its role in cell signaling pathways, R-Ras is also a potential drug target. Many studies have suggested that inhibitors of R-Ras could be effective in treating various types of cancer. For example, inhibitors of R-Ras have been shown to be effective in treating breast and ovarian cancer, as well as in inhibiting the growth of prostate cancer cells. In addition, R-Ras has been shown to be involved in the regulation of cell cycle progression, which could make it a useful target for cancer treatment.

Overall, R-Ras is a protein that is highly relevant to the study of cancer biology and the development of new treatments. Its similar structure to TGR makes it a potential drug target, and its role in cell signaling pathways makes it a promising target for cancer treatment. Further research is needed to fully understand the functions of R-Ras and its potential as a drug target.

Protein Name: RAS Related

Functions: Regulates the organization of the actin cytoskeleton (PubMed:16537651, PubMed:18270267). With OSPBL3, modulates integrin beta-1 (ITGB1) activity (PubMed:18270267)

The "RRAS Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RRAS comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets